GlassScriptPhysician profile
Daniel B Garcia
NPI 1689699449
$1,547.90
in general payments reported to CMS, 2019-2025
11 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $36.25 · 2021: $333 · 2022: $110 · 2023: $20.59 · 2024: $428 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $331.91 | 2019-2021 | |
| Novo Nordisk INC | $275.49 | 2020-2024 | Rybelsus, Ozempic |
| Nxstage Medical, INC. | $196.23 | 2021 | |
| Terumo Medical Corporation | $164.14 | 2024 | Metacross Otw |
| Astrazeneca Pharmaceuticals LP | $153.92 | 2019-2025 | Farxiga |
| Boston Scientific Corporation | $124.71 | 2025 | General - Atherectomy |
| Genzyme Corporation | $122.06 | 2024 | |
| Abiomed | $113.37 | 2024 | Impella |
| Lilly USA, LLC | $29.99 | 2019 | |
| Horizon Therapeutics Plc | $20.59 | 2023 | Krystexxa |
| Abbott Laboratories | $15.49 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.